GoodRx and MedImpact Announce Program to Ensure Seamless Access to Affordable Prescriptions
13 9월 2023 - 10:00PM
Business Wire
Companies team up at the pharmacy counter to
drive medication adherence and better health outcomes
GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings
and information, and MedImpact, the independent pharmacy benefit
manager (PBM) and health solutions company, today announced a new
savings solution designed to integrate GoodRx’s prescription
pricing in a seamless experience at the pharmacy counter. Now, when
an eligible MedImpact member fills a prescription for a generic
medication, it will automatically compare their benefit and the
GoodRx price and then deliver the lowest one. The amount paid will
be applied to the member’s deductible.
“This solution allows us to meet Americans where they are by
providing them with low prices on their prescriptions without the
need for them to compare costs on their own,” said Cynthia Meiners,
Strategic Program Development Officer at GoodRx. “We are bringing
together the best of what GoodRx does with the best of what
MedImpact does to make it incredibly convenient for MedImpact’s
members to start and stay on their prescribed treatments, and to
fully integrate their clinical data. We truly feel the future of
healthcare lies in these types of integrations.”
The collaboration achieved by integrating GoodRx’s price
comparison technology with MedImpact’s advanced technology platform
allows both companies to deliver more savings without any
additional work on the part of the consumer. In addition, members
will benefit from the seamless data integration this program
provides. Through MedImpact’s rigorous drug safety review, which
includes thousands of health and safety checks, patients will be
alerted about any negative drug interactions.
“We are delivering to clients a full portfolio of health,
wellness and savings solutions and we see this program as an
important part of it,” Marcus Sredzinski, Pharm D, General Manager
and MedImpact Senior Vice President. “This delivers hassle-free
savings to members, while helping payers capture clinical and
adherence data they may have otherwise missed.”
GoodRx is actively working to access new lives by expanding its
prescription savings reach by partnering with pharmacy benefit
managers and their plan sponsors to collaboratively integrate into
the insurance benefit market. Through these programs with CVS
Caremark, Express Scripts, and MedImpact, GoodRx savings are
seamlessly integrated at point-of-sale with three major PBMs that
reach over 60% of insured lives.
This new program will become available to eligible MedImpact
members starting January 1, 2024.
About GoodRx
GoodRx is a leading resource for healthcare savings and
information that makes healthcare affordable and convenient for all
Americans. We offer consumers free access to transparent and lower
prices for brand and generic medications, affordable and convenient
medical provider consultations via telehealth, and comprehensive
healthcare research and information. Since 2011, we have helped
consumers save over $60 billion and are one of the most downloaded
medical apps over the past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
About MedImpact
For more than 30 years, MedImpact has been building, delivering,
and reimagining pharmacy benefit solutions for healthcare payers
who face complex and dynamic challenges. As the leading independent
PBM, we offer clients the clarity they need to make care and cost
decisions; control over a powerful suite of solutions that manage
pharmacy spend; and confidence that comes from a proven PBM partner
who is fully aligned with their goals and invested in their future.
Learn more at www.medimpact.com or follow us on LinkedIn and
Twitter @MedImpact.
GoodRx Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding consumer savings, the demand and success of
MedImpact’s savings program and the benefits to consumers from such
offering, and GoodRx’s plans and objectives. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, risks relating to changes in medication pricing
which are significantly impacted by pricing structures negotiated
by industry participants, GoodRx’s ability to achieve broad market
education and change consumer purchasing habits, and the important
factors discussed in the sections entitled “Risk Factors” in
GoodRx’s Annual Report on Form 10-K for the year ended December 31,
2022, as updated by GoodRx’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2023, and GoodRx’s other filings with the
SEC. These factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
current expectations and projections as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230913312925/en/
Lauren Casparis press@goodrx.com
GoodRx (NASDAQ:GDRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GoodRx (NASDAQ:GDRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024